plerixafor has been researched along with Leukemia, Myeloid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bornhäuser, M; Brenner, S; Jacobi, A; Koch, S; Lehmann, R; Malech, HL; Müller, K; Ryser, M; Thiede, C; Thieme, S; Ugarte, F | 1 |
1 other study(ies) available for plerixafor and Leukemia, Myeloid
| Article | Year |
|---|---|
Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
Topics: Acute Disease; Animals; Benzylamines; Bone Marrow Cells; Cell Movement; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cyclams; Flow Cytometry; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukemia, Experimental; Leukemia, Myeloid; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; STAT5 Transcription Factor; Transplantation, Heterologous; Tumor Suppressor Proteins | 2010 |